Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Shibaki R, Ozawa Y, Noguchi S, Murakami Y, Takase E, Azuma Y, Maebeya M, Sugimoto T, Hayata A, Hayakawa T, Tamaki S, Nakanishi M, Teraoka S, Akamatsu H. Shibaki R, et al. Among authors: nakanishi m. Cancer Med. 2022 Oct;11(20):3743-3750. doi: 10.1002/cam4.4750. Epub 2022 Apr 17. Cancer Med. 2022. PMID: 35434933 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: nakanishi m. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Among authors: nakanishi m. Clin Lung Cancer. 2021 Nov;22(6):e833-e841. doi: 10.1016/j.cllc.2021.04.007. Epub 2021 Apr 27. Clin Lung Cancer. 2021. PMID: 34049821 Free article.
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Harutani Y, Ozawa Y, Murakami E, Sato K, Oyanagi J, Akamatsu H, Yoshikawa T, Shibaki R, Sugimoto T, Furuta K, Teraoka S, Tokudome N, Hayata A, Ueda H, Nakanishi M, Koh Y, Yamamoto N. Harutani Y, et al. Among authors: nakanishi m. Cancer Immunol Immunother. 2022 Sep;71(9):2109-2116. doi: 10.1007/s00262-022-03141-4. Epub 2022 Jan 16. Cancer Immunol Immunother. 2022. PMID: 35037070 Free PMC article.
Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Sato K, et al. Among authors: nakanishi m. Lung Cancer. 2018 Dec;126:230-231. doi: 10.1016/j.lungcan.2018.11.007. Epub 2018 Nov 18. Lung Cancer. 2018. PMID: 30459086 Free article. No abstract available.
2,170 results